Eprex in the management of anemia related to lymphoproliferative disorders

We report results of therapy with recombinant human erythropoietin alpha (Eprex) in patients (pts) with multiple myeloma and chronic lymphocytic leukaemia during chemotherapy. 14pts were included in this study. A level of endogenous erythropoietin, a serum iron binding capacity, and a level of serum iron were evaluated before the start of treatment. Oral iron medication prescribes in cases of established iron deficiency. A rate of increase of hemoglobin level was monitored on week 4, 8, and 12. Objective effect was achieved in 12 (85,7%) pts on 12-th week of treatment. Normal and moderately increased endogenous erythropoietin level was not a negative predicted factor for Eprex efficacy. We did not reveal complications of study drug. Therapy was executed in out-patient treatment regimen. We documented decrease of hospitalization necessity and transfusion dependence. An important treatment outcome resulted in improving of quality of life.

1. Ludwig H., Birgegard G., Barret-Lee PJ. et al. Prevalence and management of anemia in patient with haematologic malignancies and solid tumors: results from the European Cancer Anemia Survey. Program and abstracts of the 44th Annual Meeting of the American Society of Hematology. December 6-10, 2002. Philadelphia, Pennsylvania. Abstr 884.

2. Salvarini C., Casali B., Salvo D. et al. The role of interleukine-1, erythropoietin and red cell bound immunoglobulins in anemia of rheumatoid arthritis. Clin Exp Rheumatol 2000;9:2414-6.

3. Bottini A., Berruti A., Brizz M.P. et al. ASCO 2002. p. 47 (abstr 187).

4. Frommhold H., Guttenberger R., Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strahlenther Oncol 1998;174(Suppl 4):31-4.

5. Crawford J., Robert F. et al. Epoetin alfa 40000u once weekly maintains hemoglobin in advanced non-small-cell lung cancer patients receiving first - line chemotherapy. Proc ASCO 2003;22:628 (abstr 2527).

6. Методическое письмо «Лечение анемии у больных со злокачественными новообразованиями». Министерство здравоохранения и социального развития РФ, 27.10.2005, №7612/14.

7. Fillet G., Begum Y., Baldelli L. Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood 1989;74:844-51.

8. Littlewood T.J., Bajetta E., Nortier J.W.R. et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74.

9. Seidenfeld J., Piper M., Flamm C. et al. Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001;93:1204-14.

10. Бредер В.В., Бесова Н.С., Гобунова ВА Лечение анемии при злокачественных опухолях. Эффективность Эпрекса. Эффективная фармакотерапия в онкологии, гематологии, радиологии 2005;(1):1-4.

11. Возный Э.К., Ганьшина И.П. Применение Эпрекса в онкологической практике. Фарматека 2003;(14):1-5.

12. Жукова Л.Г., Ганьшина И.П. Эпоэ-тин альфа (рекомбинантный человеческий эритропоэтин) в лечении анемии при элокачественных новообразованиях: клинические рекомендации. Фарматека 2005;0 (Спецвыпуск Онкология ASCO-2005):1-5.

13. Павлов А.Д., Морщакова Е.Ф., Румянцев А.Г. Анемия при злокачественных новообразованиях: патогенез и лечение рекомбинантным человеческим эритропоэтином. Современ онкол 2002;4(2):50-4.